ArticleAmerican journal of translational research2018
Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines.
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease.Life (Basel, Switzerland) · 2026Article
- Rare of Gaucher's Disease Complication of Splenic Multiple Gaucheroma.Endocrine, metabolic & immune disorders drug targets · 2025Article
- Future is now: an Australasian perspective on disease-modifying trials in Parkinson's and prodromal disease.BMJ neurology open · 2025Article
- Article
- Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review.Molecular genetics & genomic medicine · 2024Review
- Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.International journal of molecular sciences · 2023Article
- Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.PloS one · 2021Article
- Article
- The natural history of type 2 Gaucher disease in the 21st century: A retrospective study.Neurology · 2020Article
- Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates Autophagy.Biomolecules · 2020Article
- Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases.Journal of clinical medicine · 2020Article
- Glucocerebrosidase as a therapeutic target for Parkinson's disease.Expert opinion on therapeutic targets · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The knowledge of individual response to a therapy, which can be assesed by
Indexed as
Identifiers
30662625PMC6291725W2985181372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.